210755-45-6

210755-45-6 structure

Name: CP-471474
Chemical Name: 2-[[4-(4-fluorophenoxy)phenyl]sulfonylamino]-N-hydroxy-2-methylpropanamide
CAS Number: 210755-45-6
Molecular Formula: C₁₆H₁₇FN₂O₅S
Molecular Weight: 368.38000
Catalog: Signaling Pathways Metabolic Enzyme/Protease MMP
Create Date: 2016-12-21 20:28:51
Modify Date: 2024-01-27 07:23:41
CP-471474 is an orally active and pan MMP inhibitor, with IC50 values of 1170 nM (MMP-1), 0.7 nM (MMP-2), 16 nM (MMP-3), 13 nM (MMP-9) and 0.9 nM (MMP-13), respectively[1][2].

Name	2-[[4-(4-fluorophenoxy)phenyl]sulfonylamino]-N-hydroxy-2-methylpropanamide
Synonyms	2-[[[4-(4-Fluorophenoxy)phenyl]sulfonyl]amino]-N-hydrox y-2-methylpropanamide PF-1626077 HMS3262O11 UNII-96U47H947L

Description	CP-471474 is an orally active and pan MMP inhibitor, with IC50 values of 1170 nM (MMP-1), 0.7 nM (MMP-2), 16 nM (MMP-3), 13 nM (MMP-9) and 0.9 nM (MMP-13), respectively[1][2].
Related Catalog	Research Areas >> Inflammation/Immunology Signaling Pathways >> Metabolic Enzyme/Protease >> MMP
Target	MMP-2:0.7 nM (IC50) MMP-13:0.9 nM (IC50) MMP-9:13 nM (IC50) MMP-3:16 nM (IC50) MMP-1:1170 nM (IC50)
In Vivo	CP-471474 plasma levels following subcutaneous injection are 2,020 ng/mL (1 h postdose) to 160 ng/mL (6 h postdose)[2]. CP-471,474 significantly reduces both the extent and severity of inflammation at 2 months. At 4 months, a spontaneous reduction of the inflammatory response is observed in both treated and untreated animals, and consequently no difference is observed between both[2]. CP-471474 significantly decreases the destructive lesions mainly at 2 months and also at 4 months[2]. Animal Model: Guinea pigs weighing 400 to 450 g (COPD)[2]. Dosage: 20 mg/kg (also supplemented daily by the diet (200 mg/200 g powdered chow)). Administration: Subcutaneously (in 20% ethanol/80% polyethylene glycol), once a day during the entire course. Result: Lungs derived from smoking animals treated with the compound demonstrated a statistically significant reduction in the destructive lesions. Showed an increase of both pro–MMP-9 and its active form (lanes 5 to 8) as compared with control animals.
References	[1]. L E Rohde, et al. Matrix metalloproteinase inhibition attenuates early left ventricular enlargement after experimental myocardial infarction in mice. Circulation. 1999 Jun 15;99(23):3063-70. [2]. Moisés Selman, et al. Matrix metalloproteinases inhibition attenuates tobacco smoke-induced emphysema in Guinea pigs. Chest. 2003 May;123(5):1633-41.

Molecular Formula	C₁₆H₁₇FN₂O₅S
Molecular Weight	368.38000
Exact Mass	368.08400
PSA	116.60000
LogP	4.49230

Symbol	GHS07
Signal Word	Warning
Hazard Statements	H302
RIDADR	NONH for all modes of transport

210755-45-6	478341-55-8
110703-94-1	83003-12-7
111469-38-6	850467-66-2
532435-68-0	1080622-86-1
220941-93-5	212790-31-3